Reported resultsCompany-reported
What was reported
SOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 28, 2026 · Open the source ↗
What the evidence supports
ClearPoint Neuro published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $12.1 million | “• Reported third quarter revenue of $12.1 million, representing 36% overall growth, including the recently acquired IRRAflow Portfolio;” Mentions: revenue |
| $5.4 million | “• Neurosurgery navigation and therapy, which includes navigation, laser, drill and IRRAflow products, increased 59% to $5.4 million in the quarter;” |
| $1.7 million | “• Achieved record capital equipment and software revenue of $1.7 million, representing 68% growth in the quarter, including the recently acquired IRRAflow equipment;” Mentions: revenue |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineClearPoint Neuro Reports Third Quarter 2026 ResultsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 28, 2026 · Open the source ↗
Press release lead paragraphSOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 28, 2026 · Open the source ↗
Amount stated in press release• Reported third quarter revenue of $12.1 million, representing 36% overall growth, including the recently acquired IRRAflow Portfolio;U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 28, 2026 · Open the source ↗
Amount stated in press release• Neurosurgery navigation and therapy, which includes navigation, laser, drill and IRRAflow products, increased 59% to $5.4 million in the quarter;U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 28, 2026 · Open the source ↗
Amount stated in press release• Achieved record capital equipment and software revenue of $1.7 million, representing 68% growth in the quarter, including the recently acquired IRRAflow equipment;U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 28, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:55 UTC
ClearPoint Neuro Reports Third Quarter 2026 Results
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.